We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
+37.1%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$622M
AUM Growth
+$195M
Cap. Flow
+$80.5M
Cap. Flow %
12.95%
Top 10 Hldgs %
55.49%
Holding
44
New
12
Increased
14
Reduced
4
Closed
6
Avg Time Held
1.1 years
Top 10 Avg Time Held
1 year
Top 20 Avg Time Held
1.1 years

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CGEM icon
1
Cullinan Therapeutics
CGEM
$577M
$130M 20.95%
7,648,268
– –
2021 Q1
12 quarters
GERN icon
2
Geron
GERN
$561M
$34.6M 5.56%
10,475,675
-239,945
-2% -$538K
2021 Q3
10 quarters
IOVA icon
3
Iovance Biotherapeutics
IOVA
$3.19B
$32.6M 5.24%
2,200,000
-1,089,470
-33% -$12.7M
2022 Q2
7 quarters
ZNTL icon
4
Zentalis Pharmaceuticals
ZNTL
$134M
$23.9M 3.84%
+1,516,183
New +$20.9M
2024 Q1
0 quarters
ITOS icon
5
DELISTED
iTeos Therapeutics
ITOS
$23.8M 3.83%
1,745,943
– –
2020 Q3
14 quarters
STRO icon
6
Sutro Biopharma
STRO
$143M
$23.1M 3.72%
+409,662
New +$18.1M
2024 Q1
0 quarters
CRNX icon
7
DELISTED
Crinetics Pharmaceuticals
CRNX
$22.5M 3.62%
480,588
+2,354
+0.5% +$92.1K
2021 Q3
10 quarters
OLMA icon
8
Olema Oncology
OLMA
$615M
$22.1M 3.56%
1,953,690
+96,554
+5% +$1.25M
2023 Q2
3 quarters
MDGL icon
9
Madrigal Pharmaceuticals
MDGL
$8.81B
$16.4M 2.64%
61,399
+20,489
+50% +$4.83M
2022 Q2
7 quarters
NTRA icon
10
Natera
NTRA
$39.6B
$15.8M 2.54%
+172,413
New +$13M
2024 Q1
0 quarters
HOWL icon
11
Werewolf Therapeutics
HOWL
$46M
$15.5M 2.49%
2,388,011
– –
2021 Q2
11 quarters
MLTX icon
12
MoonLake Immunotherapeutics
MLTX
$942M
$14.9M 2.39%
296,050
+1,474
+0.5% +$80K
2023 Q2
3 quarters
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$14.7M 2.37%
871,149
+206,163
+31% +$3.07M
2023 Q2
3 quarters
INSM icon
14
Insmed
INSM
$31B
$14.4M 2.32%
530,794
+2,644
+0.5% +$74K
2022 Q4
5 quarters
ALXO icon
15
ALX Oncology
ALXO
$137M
$14.1M 2.27%
1,268,471
+3,712
+0.3% +$52.1K
2023 Q4
1 quarter
VKTX icon
16
Viking Therapeutics
VKTX
$3.16B
$12.3M 1.98%
150,000
-175,284
-54% -$7.8M
2023 Q3
2 quarters
NTLA icon
17
Intellia Therapeutics
NTLA
$1.4B
$11.9M 1.91%
432,598
+50,000
+13% +$1.39M
2021 Q3
10 quarters
RGNX icon
18
Regenxbio
RGNX
$473M
$11.6M 1.86%
549,078
– –
2022 Q3
6 quarters
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$1.68B
$11.5M 1.84%
+245,590
New +$11.6M
2024 Q1
0 quarters
MORF icon
20
DELISTED
Morphic Holding
MORF
$11.5M 1.84%
325,333
+1,591
+0.5% +$53.3K
2023 Q3
2 quarters
ETNB icon
21
DELISTED
89bio
ETNB
$11.3M 1.81%
+967,742
New +$10.7M
2024 Q1
0 quarters
VRDN icon
22
Viridian Therapeutics
VRDN
$3.4B
$10.8M 1.73%
614,010
+514,010
+514% +$10M
2023 Q2
3 quarters
FULC icon
23
Fulcrum Therapeutics
FULC
$282M
$10.7M 1.73%
+1,137,108
New +$10.2M
2024 Q1
0 quarters
XERS icon
24
Xeris Biopharma Holdings
XERS
$3.1B
$9.21M 1.48%
4,166,496
+319,264
+8% +$826K
2023 Q2
3 quarters
AXSM icon
25
Axsome Therapeutics
AXSM
$6.8B
$9.11M 1.46%
114,127
+20,740
+22% +$1.74M
2022 Q4
5 quarters

Similar funds

MPM BioImpact's Q1 2024 Portfolio in Review

As of Q1 2024, MPM BioImpact held 44 positions worth $622M, up 46% from $427M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

MPM BioImpact deployed $80.5M of net new capital in Q1 2024, opening 12 new positions and adding to 14 existing holdings. Its largest new stake was Zentalis Pharmaceuticals: 1,516,183 shares worth $23.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $12.7M trimmed.

  • MPM BioImpact's largest Q1 2024 buy was Zentalis Pharmaceuticals: 1,516,183 shares worth $23.9M.
  • MPM BioImpact added most to Viridian Therapeutics in Q1 2024, an estimated $10M increase.
  • MPM BioImpact's biggest Q1 2024 reduction was Iovance Biotherapeutics, cutting an estimated $12.7M.
  • MPM BioImpact fully exited Karuna Therapeutics in Q1 2024, selling an estimated $16.9M.
  • MPM BioImpact's ten largest holdings make up 55% of its $622M portfolio in Q1 2024.
  • MPM BioImpact opened 12 new positions and closed 6 in Q1 2024.
  • MPM BioImpact's portfolio value rose 46% quarter-over-quarter to $622M.

Based on MPM BioImpact's 13F filing for Q1 2024, filed 15 May 2024.